New findings from the ACTIV-6 randomized clinical trial provide important confirmation of prior clinical trial results that metformin, a widely available and inexpensive medication with an established safety record, reduced the risk of clinician-diagnosed long COVID when started during acute COVID-19 infection.

Boston Children's Hospital has been awarded up to $17.25 million to serve as a participating site within the Innovative Medicine and Precision Approaches to Clinical Trials (IMPACT) Network, an international effort funded through Aligning Research to Impact Autism (ARIA). This investment is part of a major, short-term natural history and clinical endpoint study aimed at speeding up the development of urgently needed treatments for children with profound autism and related neurodevelopmental disabilities (NDDs), with or without genetic causes.

About The Study: During a press conference on September 22, 2025, President Trump and top health officials endorsed use of leucovorin, a generic drug formulated from folinic acid, for treatment of autism, and urged against acetaminophen use during pregnancy, stating concerns about its risk for development of autism in children. The White House announcement was associated with large increases in internet searches over the subsequent 2 weeks, including more than 1 million additional searches for leucovorin; nearly 81,000 additional purchasing interest searches for leucovorin, folinic acid, or folate; and more than 4 million additional searches for acetaminophen with pregnancy or autism.

A team of Johns Hopkins Bloomberg School of Public Health researchers has discovered large droplets of proteins known as condensates near inactive chromosome regions within the cell nucleus that are a feature of some cancer cells and may hold clues for better anticancer strategies.

About The Study: Among trial patients discharged after hospitalization for serious infections, remote monitoring did not increase time spent alive at home but reduced it in those 65 years and older. These findings support reevaluating and tailoring remote monitoring after acute care for sepsis and lower respiratory tract infection to support further alignment with patients’ needs and desire for personalized monitoring.